Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
Trial details
- Registry ID
- NCT07916480
- Drugs studied
- Roflumilast Cream 0.3%, Vehicle Cream
TrialRedline tracks 14 clinical trials sponsored by Arcutis Biotherapeutics, Inc.: 8 Phase 3, 6 Phase 2.
Company identity checked against sources
Names as written in the registry records.
NCT07916480 · Arcutis Biotherapeutics, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT04286607 · Arcutis Biotherapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Occurrence of treatment emergent AEs (TEAEs). After: Measure: Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) Measure: Percentage of Participants With ≥1 Serious Adverse Events (SAEs).
Before: 333 participants (actual). After: 337 participants (actual).
NCT04746911 · Arcutis Biotherapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Plasma pharmacokinetic (PK) profile of ARQ-151 cream 0.3% and its major N-oxide metabolite Measure: Incidence of adverse events Measure: Incidence of application site reactions. After: Measure: Plasma Concentration of Roflumilast Following Daily Application of Roflumilast Cream 0.3% Measure: Plasma Concentration of Major N-oxide Metabolite Following Daily Application of Roflumilast Cream 0.3% Measure: Number of Participants With an Adverse Event (AE) Measure: Number of Participants With Application Site Reactions.
NCT06998056 · Arcutis Biotherapeutics, Inc.
Before: Estimated. After: Actual.
Before: 100 participants (planned). After: 101 participants (actual).
Before: Estimated. After: Actual.
Before: Jun 2026. After: 4 Dec 2025.
Before: Recruiting. After: Completed.